Fresenius (ETR:FRE) target price bumped up to 77.25EUR, released a ratings update earlier today by Joh. Berenberg Gossler & Co. KG
- Updated: September 24, 2016
Displaying a price of 72.84EUR, Fresenius (ETR:FRE) traded 0.00% even on the day. With the last close up 0.00% from the 200-day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time. FRE has recorded a 50-day moving average of 0.00EUR and a two hundred day average of 0.00EUR. Trade Volume held steady, with 0 shares of FRE changing hands on par with the typical 0
Reporting as potential upside of 0.06%, Joh. Berenberg Gossler & Co. KG raised the target price of Fresenius (ETR:FRE) to 77.25EUR
On Saturday September 24, 2016, Joh. Berenberg Gossler & Co. KG reported on Fresenius (ETR:FRE) increased the target price from 0.00EUR to 77.25EUR that suggested an upside of 0.06%.
Fresenius has 52 week low of 0.00EUR and a 52 week high of 0.00EUR and has a total market value of 0 EUR.
Brief Synopsis About Fresenius (ETR:FRE)
Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company's operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.